Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Have you been popping omega-3 pills hoping to improve your memory or keep your brain sharp as you age? New research suggests they may not deliver the cognitive benefits many people expect.

A clinical trial, published in the journal eBioMedicine, found that omega-3 supplements did not improve memory, cognition, or brain health in older adults at risk of Alzheimer's disease.

Omega-3 fish oil and algae-based supplements have long been promoted as a way to protect against dementia and Alzheimer's disease. However, the new randomized, double-blind, placebo-controlled trial — considered the gold standard in medical research — found no evidence that these supplements slowed cognitive decline or protected the brain.

The study was led by researchers at the University of Southern California and included 365 adults aged 55 to 80 who rarely consumed fish, a natural source of omega-3 fatty acids.

"We all wish there was a silver bullet for preventing Alzheimer's, but our findings showed that fish oil supplements do not appear to protect brain health," said Hussein Naji Yassine, director of the USC Center for Personalized Brain Health and lead investigator of the study.

"While omega-3s play an important role in forming brain cell connections needed for cognition, our results do not support fish oil supplements as a preventive measure against Alzheimer's," he added.

How The Study Was Conducted?

Also read: Kim Kardashian Says She Takes 35 Supplements Daily, Suffers From 'Pill Fatigue'

Researchers recruited 365 adults who were considered at elevated risk for Alzheimer's disease. Nearly half (47 per cent) carried the APOE4 gene, the strongest known genetic risk factor for late-onset Alzheimer's.

Participants were randomly assigned to receive either a daily omega-3 supplement or a placebo.

The supplement contained 2,000 mg of docosahexaenoic acid (DHA), an omega-3 fatty acid essential for brain function.

The researchers first examined whether DHA from the supplements could reach the brain. By measuring DHA levels in cerebrospinal fluid — the liquid surrounding the brain and spinal cord — they found a 17 per cent increase after six months, confirming that the nutrient successfully reached its target.

The team then assessed memory and cognitive performance at the beginning of the study and again two years later.

Despite higher DHA levels in the brain, participants who received the supplements performed no better on memory and cognitive tests than those taking the placebo. Brain scans also revealed no difference in shrinkage of the hippocampus, a memory-related brain region that commonly deteriorates with aging and Alzheimer's disease.

What Works Instead? A Healthy Lifestyle

The researchers emphasized that maintaining overall health remains the most effective strategy for preserving brain function and reducing Alzheimer's risk.

"Staying healthy throughout life remains the most powerful tool we have for reducing Alzheimer's risk, including regular exercise, quality sleep, and a balanced diet," said Yassine.

He compared brain health to maintaining a vehicle.

"Living a healthy lifestyle is the brain's equivalent of getting regular car maintenance and high-quality oil changes. The brain is more likely to lose function if health issues elsewhere in the body go unaddressed, just as an engine eventually fails without proper maintenance."

Read More: Sickle Cell Disease: Why India Must Add Curative Treatment to Meet Its 2047 Elimination Goal

What's Next?

Yassine and his colleagues are now investigating why omega-3 supplements can successfully reach the brain yet fail to produce measurable cognitive benefits.

The team is also exploring new therapies that could help the brain make better use of omega-3 fatty acids and potentially preserve cognitive function as people age.

A parliamentary committee in Canada has recommended that the country's assisted dying laws continue to exclude people whose sole underlying condition is a mental illness.

According to the committee's report, Canada's assisted dying framework should "indefinitely exclude" individuals whose only medical condition is a mental illness.

Canada first passed its assisted dying legislation, known as Bill C-14, in 2016, marking a significant development in healthcare and personal autonomy.

Officially known as Medical Assistance in Dying (MAID), the law initially applied only to adults who were terminally ill. However, eligibility for MAID has remained one of the country's most contentious healthcare issues over the past decade, with plans to expand access delayed twice.

Committee Recommends Permanent Exclusion

The 98-page report by the joint House and Senate committee on Medical Assistance in Dying contains a single recommendation: that Canada "indefinitely exclude persons whose sole underlying medical condition is a mental illness from eligibility for medical assistance in dying", according to the BBC.

The report noted a "divergence of perspectives" on the issue and highlighted concerns raised during testimony about the "pressing need for increased and more equitable access to adequate mental health services".

However, some committee members disagreed with the findings and published a dissenting report, arguing that the process was "fundamentally flawed", "biased", and favored testimony from those opposed to expanding MAID. Canada's government must respond to the report by July 11.

Also read: Noelia Castillo: 25-year-old Spanish Woman Dies By Euthanasia After Long Legal Battle

What Does Canada's MAID Law Say?

When MAID was introduced in 2016, it was available only to adults who were terminally ill.

The eligibility criteria were strict. Individuals had to be suffering from a "serious and incurable illness", be in an "advanced state of irreversible decline", experience "intolerable suffering", and have a natural death that was "reasonably foreseeable".

This legal pathway became known as Track 1. Modelled on end-of-life care, it primarily served people with terminal cancer or other severe illnesses who wanted greater control over the dying process. Track 1 remains a relatively swift procedure, with some patients receiving MAID within a day of applying.

Expansion Beyond Terminal Illness

Read More: Passive Euthanasia: Harish Rana’s Case May Reshape End-of-life Protocols, Say Experts

However, many Canadians living with severe non-terminal conditions argued that they were excluded from the law. These included people with degenerative diseases, chronic pain, or spinal injuries who experienced significant suffering but were not nearing death. Many requested MAID but were routinely denied.

In 2019, the country introduced Bill C-7 in 2021, creating Track 2 and extending MAID eligibility to people with serious, incurable conditions causing enduring suffering even when death was not foreseeable.

Track 2 includes additional safeguards, including a 90-day assessment period, evaluation by two independent clinicians, and consultation with specialists when necessary.

Ongoing Debate Over Mental Illness Eligibility

Despite its stricter safeguards and ethical complexities, Track 2 MAID has steadily gained use. In 2023, there were 622 deaths under Track 2 compared with 14,721 under Track 1.

Supporters view Track 2 as a compassionate option for people living with severe, non-terminal suffering, while critics argue it risks exposing vulnerable populations to premature death.

In 2023, Canada first delayed eligibility for MAID for people whose sole condition was a mental illness by one year, citing concerns that the healthcare system was not ready for the expansion. The government later delayed implementation again until March 17, 2027.

Along with the second delay, the government recommended that a parliamentary committee undertake a comprehensive review of the proposal.

MAID Accounts For About 5% of Deaths in Canada

According to the latest available figures from 2024, MAID accounts for around 5 per cent of all deaths in Canada. About 96 per cent of MAID cases involved people whose deaths were reasonably foreseeable, most of them terminal cancer patients.

The remaining 4 per cent involved patients whose deaths were not imminent but who had a "grievous and irremediable medical condition".

The United States is witnessing a rise in cases of Powassan virus disease, a rare but potentially deadly illness transmitted through tick bites. Unlike many other tick-borne diseases, Powassan virus can be transmitted within 15 minutes of a tick attaching to the skin, making prevention and awareness especially important.

According to the US Centers for Disease Control and Prevention (CDC), tick exposure can occur throughout the year, although ticks are most active during the warmer months between April and September.

Emergency physician Dr. Rick Pescatore recently highlighted the growing threat in a TikTok video post, warning that many people remain unaware of the virus despite its severe health consequences.

"There's a new and deadly tick virus that's spreading across the United States, and you probably haven't heard about it," he said.

Pescatore emphasized the seriousness of the infection, noting that "about one in 10 people with severe disease die, while around half of survivors may experience permanent neurological damage". He also claimed that reported cases have increased steadily over the past decade.

Several state health departments have urged residents to take precautions after reporting cases of the rare disease.

In one recent case, a 66-year-old man from New Hampshire was hospitalized for several weeks after contracting the virus. After initially being admitted to Concord Hospital, he was later transferred to Massachusetts General Hospital for specialized care.

What Is Powassan Virus?

Also read: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant

The Powassan virus is named after the town of Powassan in Ontario, Canada, where it was first identified in 1958. It belongs to the flavivirus family, which also includes viruses that cause Zika, dengue, and West Nile fever.

The virus is primarily spread by the black-legged tick (Ixodes scapularis), also known as the deer tick, which is also responsible for transmitting Lyme disease.

However, unlike Lyme disease—which generally requires a tick to remain attached for more than 24 hours before transmission—Powassan virus can be transmitted in as little as 15 minutes, according to the Massachusetts Department of Public Health.

Symptoms of Powassan Virus Infection

Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn

Symptoms typically develop between seven and 30 days after a tick bite and may include:

• Fever
• Headache
• Vomiting
• Weakness
• Confusion
• Loss of coordination
• Seizures
• Difficulty speaking

These complications can lead to long-term neurological damage. According to Yale Medicine, approximately 10 per cent of severe cases are fatal, while nearly 50 per cent of survivors experience lasting neurological problems.

No Vaccine or Treatment Available

One of the most concerning aspects of the Powassan virus is that there is currently no vaccine or antiviral treatment available.

Unlike Lyme disease, which can be treated with antibiotics, Powassan virus has no specific cure. Medical care focuses on managing symptoms and supporting patients with severe disease.

As a result, prevention remains the most effective defense against infection.

How to Prevent Tick Bites

The CDC and the National Institutes of Health (NIH) recommend the following measures to reduce the risk of tick bites:

• Wear long-sleeved shirts and long pants when outdoors
• Choose light-colored clothing to make ticks easier to spot
• Tuck pants into socks or seal gaps in clothing
• Use insect repellents containing DEET, picaridin, or permethrin
• Stay in the center of hiking trails and avoid brushing against vegetation
• Check your body, clothing, pets, and outdoor gear for ticks after spending time outside
• Shower and wash clothing in hot water soon after returning indoors

If you find a tick attached to your skin, remove it promptly using fine-tipped tweezers.